- Pfizer pays a quarterly dividend of $0.43 per share, equal to $1.72 annually and a forward yield of 6.13%.
- PFE dividends are supported by trailing free cash flow of about $2.35 per share, although payout growth remains limited.
- Pfizer may suit diversified income investors, but it has not recently delivered meaningful dividend growth.
Dividend Snapshot
Pfizer (NYSE: PFE) pays a quarterly dividend of $0.43 per share, unchanged from the prior payment. That equates to $1.72 annually and a forward PFE dividend yield of 6.13% at a share price near $28.07.
For investors who owned shares before the July 24 ex-dividend date, the latest payment is scheduled for September 1. New buyers should focus on the next declared ex-dividend date rather than purchasing solely to capture a payment already earned by prior holders.
The yield is slightly above Pfizer’s 5.82% five-year average yield, suggesting the market continues to demand a relatively high income return to own the stock. That can create an opportunity for yield-focused investors, but it also reflects uncertainty around earnings recovery and future growth.
Dividend Safety
The dividend appears more supportable through cash flow than through Pfizer’s headline earnings multiple. Pfizer reports trailing free cash flow of about $2.35 per share, compared with its $1.72 annual dividend.
That implies roughly 73% cash-flow coverage, leaving a cushion but not an exceptionally wide one for a major pharmaceutical company. Investors should monitor debt reduction, acquisition spending, drug-development costs, and operating cash flow in coming quarters.
Pfizer’s current ratio is 1.27, while debt represents about 42% of capital. These figures do not signal an immediate dividend problem.
Pfizer’s trailing P/E ratio of 36.9 also deserves context. Dividend investors should prioritize cash generation and management’s dividend commitment over the P/E alone.
Growth Outlook
PFE is presently better suited to investors seeking current income than those pursuing fast-rising payouts. Its one-year dividend growth rate is just 0.58%, while its five-year annualized growth rate is 2.36%.
In practical terms, Pfizer has maintained its payout but has not delivered meaningful inflation-beating dividend growth recently. Its Chowder score, which combines current yield and five-year dividend-growth rate, is 8.49.
Valuation and Investor Takeaway
At about $28.07, Pfizer trades roughly 2.4% below its 52-week high of $28.75 and about 19% above its 52-week low of $23.58. The market appears to be pricing in some operational stabilization, reducing the margin of safety compared with the lows.
For income investors, PFE can fit as a diversified, higher-yield healthcare holding for those comfortable with modest payout growth. Pfizer’s 6.1% dividend yield is appealing and presently cash-flow covered, but the investment case rests on dividend maintenance and business recovery rather than rapid annual dividend increases.
